Back to results
US 2021/0060100 A1Published application
Phage therapy of e coli infections
AssigneePherecydes Pharma
InventorsFLAVIE POUILLOT, HÉLÈNE BLOIS
Life of this patent
Estimating the term…
Abstract
The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.
Claims15
An antibacterial composition comprising at least one bacteriophage having lytic activity to an Escherichia coli (E. coli) strain, said at least one bacteriophage being selected from the bacteriophages having a genome comprising a nucleotide sequence selected from any one of SEQ ID NOs:
- 1 to 15 or a sequence having at least 90% identity thereto.
Dependencies are inferred from the claim text.